SUVN D4010

Drug Profile

SUVN D4010

Alternative Names: SUVN-D4010

Latest Information Update: 28 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Suven Life Sciences
  • Class Antidementias
  • Mechanism of Action Serotonin 4 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Alzheimer's disease; Schizophrenia

Most Recent Events

  • 21 Jul 2017 Suven Life Sciences receives patent for serotonin 4 compounds in Australia
  • 16 Jul 2017 Efficacy, pharmacokinetics and adverse events data from two phase I trials in Healthy volunteers presented at the Alzheimer's Association International Conference 2017 (AAIC-2017)
  • 23 Jan 2017 Suven Life Sciences has patent protection for new chemical entities covering the class of selective 5-HT4 compounds for the treatment of neurodegenerative disorders in Australia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top